Nimotuzumab Formulation for Low Viscosity High Concentration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of nimotuzumab monoclonal antibody for cancer treatment face challenges in achieving high concentration, stability, low turbidity, and low viscosity, particularly for subcutaneous and intramuscular administration, which are essential for chronic use and self-administration, and existing methods often require the use of hyaluronidase enzyme for permeability.
Innovation Solution
Development of pharmaceutical formulations with nimotuzumab concentrations between 100 and 210 mg/mL, using specific combinations of buffer substances, surfactants, amino acids, and carbohydrates, such as histidine buffer, polysorbate, and sucrose, which do not require hyaluronidase for stability and permeability, allowing for stable, low-viscosity liquid or lyophilized forms suitable for subcutaneous and intramuscular administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the concentration of nimotuzumab is increased for SC or IM administration, then the administration volume is reduced, but the viscosity and turbidity increase, affecting stability and injectability
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the concentrations of multiple excipients (histidine buffer 5-30mM, polysorbate 0.02-0.06%, amino acids 30-150mM, carbohydrates 2-6%) to achieve a formulation that maintains stability while enabling high antibody concentration (100-210mg/mL). This multi-parameter optimization resolves the contradiction between concentration and stability.
Solution Approach 2:
The patent uses a composite formulation approach by combining multiple excipients with specific functions: histidine buffer for pH control and stability, polysorbate as surfactant to prevent aggregation, amino acids for solubility and stability, and carbohydrates for additional stabilization. This composite material strategy enables high concentration while maintaining low viscosity and turbidity.
2Ease of operation
If hyaluronidase enzyme is added to increase injection volume and permeability, then the biodistribution improves, but the formulation complexity and manufacturing requirements increase
Solution Approach 1:
The patent extracts and eliminates the hyaluronidase enzyme from the formulation, achieving the same or better results through a simplified excipient-based approach. By removing this complex enzymatic component, the formulation becomes easier to manufacture and store while still achieving adequate injection volume and tissue permeability through the optimized excipient combination.
Solution Approach 2:
The patent replaces the expensive and complex hyaluronidase enzyme with simpler, more stable excipients that can be readily manufactured and stored. The optimized combination of buffers, surfactants, and stabilizers provides a cost-effective, shelf-stable alternative that eliminates the need for specialized handling and storage requirements associated with enzymatic formulations.
3Reliability
If IV administration is used for nimotuzumab, then the therapeutic efficacy is ensured, but the administration time is long and requires qualified personnel and hospital setting
Solution Approach 1:
The patent changes the administration route parameter from intravenous to subcutaneous or intramuscular, fundamentally altering how the drug is delivered. This parameter change, enabled by the high-concentration stable formulation, reduces administration time from hours to minutes, allows patient self-administration at home, and maintains therapeutic efficacy through the optimized formulation that ensures proper absorption and bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide increased dose flexibility, reduced administration volume, and improved safety and efficacy, enabling chronic use and self-administration with high bioavailability and stability, maintaining therapeutic effectiveness and reducing adverse effects.
Implementation Method 1
a buffer substance at a range between 5 and 30 mM, with a pH value of 6.5 ± 0.5
Implementation Method 2
a surfactant at a range between 0.02 and 0.06%
Implementation Method 3
an amino acid or a mixture thereof at a range between 30 and 150 mM
Implementation Method 4
optionally a carbohydrate as stabilizer at a range between 2 and 6%
Data Source
AI summary
The present invention is related to the branches of Biotechnology and Medicine. It particularly describes highly concentrated and stable pharmaceutical formulations of the humanized monoclonal antibody nimotuzumab at a concentration within the range from 50 to 200 mg/mL. The low viscosity of these solutions allow for their administration by the subcutaneous or intramuscular routes in the treatment of cancer. These formulations are stable in both their liquid and lyophilized forms.